SCHEMBL4048612

SCHEMBL4048612

Oc1cccc(-c2n[c]n[nH]2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 10/20 0.46
HSD17B2 P37059 9/20 0.46
CYP3A4 P08684 3/20 0.45
CYP2C9 P11712 2/20 0.45
MGAM O43451 1/20 0.42
GAA P10253 1/20 0.42
SI P14410 1/20 0.42
MGAM2 Q2M2H8 1/20 0.42
PTPN1 P18031 1/20 0.42
METAP2 P50579 1/20 0.41
ESR1 P03372 2/20 0.39
ESR2 Q92731 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2B6 P20813 1/20 0.39
CYP2C19 P33261 1/20 0.39
MAPT P10636 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
PARP1 P09874 1/20 0.38
CA12 O43570 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4048514 0.80 GP6 (0.40) CYP3A4CYP2C9GAACYP1A2CYP2C19
SCHEMBL4044116 0.79 MGAM (0.42) MGAMGAASIMGAM2ESR2
SCHEMBL4046435 0.79 IDO1 (0.53) MGAMGAASIMGAM2ALDH1A1
SCHEMBL4050892 0.79 DCUN1D1 (0.49) GAAMETAP2CYP1A2MAPTRXFP1
SCHEMBL4041229 0.75 DCUN1D1 (0.52) CYP2C9GAACYP1A2CYP2B6MAPT
SCHEMBL4041568 0.71 HSD17B1 (0.47) HSD17B1HSD17B2CYP3A4CYP2C9MGAM
SCHEMBL859970 0.69 HSD17B1 (0.52) HSD17B1HSD17B2CYP3A4CYP2C9MGAM
SCHEMBL29551999 0.68 HSD17B1 (0.88) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
SCHEMBL69369 0.68 HSD17B1 (0.88) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
SCHEMBL4044205 0.68 RAB9A (0.57) CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7589096-B2 Azole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-09-15 US disclosed
EP-1566384-B1 NOVEL AZOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2009-06-17 EP disclosed
US-20080188507-A1 Novel azole derivatives MSD K.K. (JP) 2008-08-07 US disclosed
US-7365079-B2 Azole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-04-29 US disclosed
US-20060111380-A1 Novel azole derivatives MSD K.K. (JP) 2006-05-25 US disclosed
EP-1566384-A1 NOVEL AZOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188507-A1 Novel azole derivatives NPY1R, NPY5R, NPY2R HSD17B1 1461/4885HSD17B2 1397/4885CYP3A4 547/4885
US-20060111380-A1 Novel azole derivatives NPY1R, NPY5R, NPY2R HSD17B1 1225/4885HSD17B2 1168/4885CYP3A4 601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.